505 related articles for article (PubMed ID: 20047862)
41. Evaluation of the combination 5-fluorouracil, dacarbazine, and epirubicin in patients with advanced well-differentiated neuroendocrine tumors.
Walter T; Bruneton D; Cassier PA; Hervieu V; Pilleul F; Scoazec JY; Chayvialle JA; Lombard-Bohas C
Clin Colorectal Cancer; 2010 Oct; 9(4):248-54. PubMed ID: 20920998
[TBL] [Abstract][Full Text] [Related]
42. Effectiveness of Etoposide and Cisplatin vs Irinotecan and Cisplatin Therapy for Patients With Advanced Neuroendocrine Carcinoma of the Digestive System: The TOPIC-NEC Phase 3 Randomized Clinical Trial.
Morizane C; Machida N; Honma Y; Okusaka T; Boku N; Kato K; Nomura S; Hiraoka N; Sekine S; Taniguchi H; Okano N; Yamaguchi K; Sato T; Ikeda M; Mizuno N; Ozaka M; Kataoka T; Ueno M; Kitagawa Y; Terashima M; Furuse J;
JAMA Oncol; 2022 Oct; 8(10):1447-1455. PubMed ID: 35980649
[TBL] [Abstract][Full Text] [Related]
43. Multicenter retrospective analysis of systemic chemotherapy for advanced neuroendocrine carcinoma of the digestive system.
Yamaguchi T; Machida N; Morizane C; Kasuga A; Takahashi H; Sudo K; Nishina T; Tobimatsu K; Ishido K; Furuse J; Boku N; Okusaka T
Cancer Sci; 2014 Sep; 105(9):1176-81. PubMed ID: 24975505
[TBL] [Abstract][Full Text] [Related]
44. Chemotherapy in gastroenteropancreatic (GEP) neuroendocrine carcinomas (NEC): a critical view.
Fazio N; Spada F; Giovannini M
Cancer Treat Rev; 2013 May; 39(3):270-4. PubMed ID: 22819619
[TBL] [Abstract][Full Text] [Related]
45. Chemotherapy for advanced poorly differentiated pancreatic neuroendocrine carcinoma.
Ikeda M; Okuyama H; Takahashi H; Ohno I; Shimizu S; Mitsunaga S; Kondo S; Morizane C; Ueno H; Okusaka T
J Hepatobiliary Pancreat Sci; 2015 Aug; 22(8):623-7. PubMed ID: 25755102
[TBL] [Abstract][Full Text] [Related]
46. Irinotecan plus cisplatin in patients with extensive-disease poorly differentiated neuroendocrine carcinoma of the esophagus.
Okuma HS; Iwasa S; Shoji H; Takashima A; Okita N; Honma Y; Kato K; Hamaguchi T; Yamada Y; Shimada Y
Anticancer Res; 2014 Sep; 34(9):5037-41. PubMed ID: 25202088
[TBL] [Abstract][Full Text] [Related]
47. Post-first-line FOLFOX chemotherapy for grade 3 neuroendocrine carcinoma.
Hadoux J; Malka D; Planchard D; Scoazec JY; Caramella C; Guigay J; Boige V; Leboulleux S; Burtin P; Berdelou A; Loriot Y; Duvillard P; Chougnet CN; Déandréis D; Schlumberger M; Borget I; Ducreux M; Baudin E
Endocr Relat Cancer; 2015 Jun; 22(3):289-98. PubMed ID: 25770151
[TBL] [Abstract][Full Text] [Related]
48. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms.
Moertel CG; Kvols LK; O'Connell MJ; Rubin J
Cancer; 1991 Jul; 68(2):227-32. PubMed ID: 1712661
[TBL] [Abstract][Full Text] [Related]
49. Amrubicin for the treatment of neuroendocrine carcinoma of the gastrointestinal tract: a retrospective analysis of five cases.
Asayama M; Fuse N; Yoshino T; Yano T; Tahara M; Doi T; Fujii S; Ohtsu A
Cancer Chemother Pharmacol; 2011 Nov; 68(5):1325-30. PubMed ID: 21461890
[TBL] [Abstract][Full Text] [Related]
50. Phase II study of temozolomide monotherapy in patients with extrapulmonary neuroendocrine carcinoma.
Kobayashi N; Takeda Y; Okubo N; Suzuki A; Tokuhisa M; Hiroshima Y; Ichikawa Y
Cancer Sci; 2021 May; 112(5):1936-1942. PubMed ID: 33453146
[TBL] [Abstract][Full Text] [Related]
51. Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate.
Papandreou CN; Daliani DD; Thall PF; Tu SM; Wang X; Reyes A; Troncoso P; Logothetis CJ
J Clin Oncol; 2002 Jul; 20(14):3072-80. PubMed ID: 12118020
[TBL] [Abstract][Full Text] [Related]
52. Poorly differentiated gastro-entero-pancreatic neuroendocrine carcinomas: Are they really heterogeneous? Insights from the FFCD-GTE national cohort.
Walter T; Tougeron D; Baudin E; Le Malicot K; Lecomte T; Malka D; Hentic O; Manfredi S; Bonnet I; Guimbaud R; Coriat R; Lepère C; Desauw C; Thirot-Bidault A; Dahan L; Roquin G; Aparicio T; Legoux JL; Lombard-Bohas C; Scoazec JY; Lepage C; Cadiot G;
Eur J Cancer; 2017 Jul; 79():158-165. PubMed ID: 28501762
[TBL] [Abstract][Full Text] [Related]
53. Clinicopathological, treatment, and prognosis study of 43 gastric neuroendocrine carcinomas.
Liu DJ; Fu XL; Liu W; Zheng LY; Zhang JF; Huo YM; Li J; Hua R; Liu Q; Sun YW
World J Gastroenterol; 2017 Jan; 23(3):516-524. PubMed ID: 28210088
[TBL] [Abstract][Full Text] [Related]
54. Evaluating bevacizumab in combination with FOLFIRI after the failure of platinum-etoposide regimen in patients with advanced poorly differentiated neuroendocrine carcinoma: The PRODIGE 41-BEVANEC randomized phase II study.
Walter T; Malka D; Hentic O; Lombard-Bohas C; Le Malicot K; Smith D; Ferru A; Assenat E; Cadiot G; Lievre A; Kurtz JE; Dahan L; Dubreuil O; Hautefeuille V; Lepere C; Gangloff A; Elhajbi F; Coriat R; Roquin G; Bouarioua N; Granger V; Scoazec JY; Lepage C
Dig Liver Dis; 2018 Feb; 50(2):195-198. PubMed ID: 29258812
[TBL] [Abstract][Full Text] [Related]
55. A Phase III trial comparing irinotecan and cisplatin with etoposide and cisplatin in adjuvant chemotherapy for completely resected pulmonary high-grade neuroendocrine carcinoma (JCOG1205/1206).
Eba J; Kenmotsu H; Tsuboi M; Niho S; Katayama H; Shibata T; Watanabe S; Yamamoto N; Tamura T; Asamura H; ;
Jpn J Clin Oncol; 2014 Apr; 44(4):379-82. PubMed ID: 24474818
[TBL] [Abstract][Full Text] [Related]
56. A retrospective study of definitive chemoradiotherapy in patients with resectable small cell neuroendocrine carcinoma of the esophagus.
Katada C; Komori S; Yoshida T; Kawakami S; Watanabe A; Ishido K; Azuma M; Wada T; Hosoda K; Yamashita K; Hiki N; Tanabe S; Ishiyama H; Koizumi W
Esophagus; 2020 Apr; 17(2):135-140. PubMed ID: 31321580
[TBL] [Abstract][Full Text] [Related]
57. Multicentre phase II study of cisplatin-etoposide chemotherapy for advanced large-cell neuroendocrine lung carcinoma: the GFPC 0302 study.
Le Treut J; Sault MC; Lena H; Souquet PJ; Vergnenegre A; Le Caer H; Berard H; Boffa S; Monnet I; Damotte D; Chouaid C
Ann Oncol; 2013 Jun; 24(6):1548-52. PubMed ID: 23406729
[TBL] [Abstract][Full Text] [Related]
58. Etoposide? Or polysorbate-80?
Aksahin A; Colak D; Altinbas M
Indian J Cancer; 2011; 48(2):272-3. PubMed ID: 21768689
[No Abstract] [Full Text] [Related]
59. Comparison of chemotherapeutic treatment outcomes of advanced extrapulmonary neuroendocrine carcinomas and advanced small-cell lung carcinoma.
Terashima T; Morizane C; Hiraoka N; Tsuda H; Tamura T; Shimada Y; Kaneko S; Kushima R; Ueno H; Kondo S; Ikeda M; Okusaka T
Neuroendocrinology; 2012; 96(4):324-32. PubMed ID: 22572060
[TBL] [Abstract][Full Text] [Related]
60. Etoposide/cisplatin-based chemotherapy for patients with metastatic poorly differentiated carcinoma of unknown primary site.
Greco FA; Johnson DH; Hainsworth JD
Semin Oncol; 1992 Dec; 19(6 Suppl 13):14-8. PubMed ID: 1492223
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
